Immunomedics Культура компании

Mr. Peter P. Pfreundschuh, CPA, has been Chief Financial Officer at Sucampo Pharmaceuticals, Inc. since March 20, 2017. Mr. Pfreundschuh has been Consultant of Immunomedics Inc. since June 21, 2016. Mr. Pfreundschuh served as the Chief Financial Officer and Vice President of Finance at Immunomedics Inc. from September 3, 2013 to June 27, 2016. He served as the Chief Financial Officer of CircuLite, Inc. from December 2008 to July 2013. Mr. Pfreundschuh has over 15 years of business and financial experience in the life sciences industry. He served as an Executive Director of Business Development and Licensing at AstraZeneca, where he led finance and negotiations in support of new business development opportunities for all external deals and alliances. Mr. Pfreundschuh has an extensive experience with operational finance business development, executing licensing deals and strategic planning. Prior to AstraZeneca, he served at Johnson and Johnson as Controller of the R&D division and Controller/Director of Marketing and Global Business Analytics. He served as Chief Financial Officer and Treasurer for 3 Dimensional Pharmaceuticals, which was acquired by Johnson and Johnson. He served management positions at Alimenterics, Inc. and American Standard Companies, Inc., and served as a Senior Auditor at Ernst & Young, LLP. Mr. Pfreundschuh is a New Jersey Certified Public Accountant and he holds MBA degree with a concentration in finance from Rider University, a BS in accounting from Rutgers University School of Business., and has continued his education through the Executive Strategic Marketing Program in Healthcare at the Kellogg School of Management at Northwestern University.

Ms. Phyllis Parker serves as a Director of Administration and Secretary of Immunomedics Inc. Ms. Parker served as a Secretary of IBC Pharmaceuticals Inc., a Majority owned subsidiary of Immunomedics Inc.

Dr. Chau Cheng serves as Senior Director of Investor Relations and Corporate Secretary at Immunomedics Inc. Dr. Cheng served as the Senior Director of Investor Relations & Grant Management at Immunomedics Inc. Dr. Cheng served as the Director of Investor Relations & Grant Management at Immunomedics Inc. Dr. Cheng served as the Associate Director of Investor Relations & Business Analysis of Immunomedics Inc.

Dr. David M. Goldenberg founded Immunomedics Inc. in July 1982 and has been its Chief Scientific Officer since June 1, 2007. Dr. Goldenberg serves as the Chief Patent Officer of Immunomedics Inc. Dr. Goldenberg served as Chief Medical Officer at Immunomedics Inc since June 1, 2007 until December 2014. Dr. Goldenberg serves as the President of Center for Molecular Medicine and Immunology (CMMI) and its clinical unit, Garden State Cancer Center. He serves as an Adjunct Professor of Microbiology and Immunology with the New York Medical College in Valhalla, New York. Dr. Goldenberg served as the Chief Scientific Officer of Immunomedics Inc., from March 2001 to June 2003 and served as its Chief Strategic Officer from July 2003 to June 2007. He served as the Chief Executive Officer of Immunomedics Inc., from July 1982 to July 1992, from February 1994 to May 1998 and from July 1999 to March 2001. Dr. Goldenberg served as Professor of Pathology at the University of Kentucky Medical Center from 1973 to 1983 and Director of the University's Division of Experimental Pathology from 1976 to 1983. From 1975 to 1980, he served as Executive Director of the Ephraim McDowell Community Cancer Network, Inc., and from 1978 to 1980, he served as the President of the Ephraim McDowell Cancer Research Foundation, Inc., both in Lexington, Kentucky. Dr. Goldenberg serves as the Chairman of IBC Pharmaceuticals, L.L.C. Dr. Goldenberg served as the Chairman of Immunomedics Inc. since July 1982 and serves as its Director. Dr. Goldenberg has written or co-authored more than 1,300 journal articles, book chapters and abstracts on cancer research, detection and treatment and has researched and written extensively in the area of radioimmunodetection and radioimmunotherapy using radiolabeled antibodies. In 1985 and again in 1992, Dr. Goldenberg received an Outstanding Investigator grant award from the National Cancer Institute for his work in radioimmunodetection and in 1986 he received the New Jersey Pride Award in Science and Technology. Dr. Goldenberg was honored as the ninth Herz Lecturer of the Tel Aviv University Faculty of Life Sciences. In addition, he received the 1991 Mayneord 3M Award and Lectureship of the British Institute of Radiology for his contributions to the development of radiolabeled monoclonal antibodies used in the imaging and treatment of cancer. Dr. Goldenberg was also named the co-recipient of the 1994 Abbott Award by the International Society for Oncodevelopmental Biology and Medicine. Dr. Goldenberg is a graduate of the University of Chicago College and Division of Biological Sciences with a BS, the University of Erlangen-Nuremberg (Germany) Faculty of Natural Sciences with Sc.D. and the University of Heidelberg (Germany) School of Medicine with MD.

Bill Conkling serves as the Vice President Sales and Marketing of Immunomedics. Bill started at Immunomedics in May of 2018. Bill currently resides in the Greater New York City Area.

Augusto Penjasoff serves as the VP, Head of the Business Information and Technology Solutions functions of Immunomedics. Augusto started at Immunomedics in August of 2017. Augusto currently resides in the Greater New York City Area.

Prema Krishna serves as the Head of PV of Immunomedics. Prema started at Immunomedics in November of 2017. Prema currently resides in the Greater Philadelphia Area.

Trishna Goswami serves as the VP Clinical Development of Immunomedics. Trishna started at Immunomedics in June of 2018. Trishna currently resides in the Greater New York City Area.